nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—CYP1A1—Tretinoin—peripheral nervous system neoplasm	0.113	0.23	CbGbCtD
Sulindac—CYP1A1—Dacarbazine—peripheral nervous system neoplasm	0.097	0.198	CbGbCtD
Sulindac—PTGS2—Cisplatin—peripheral nervous system neoplasm	0.0572	0.117	CbGbCtD
Sulindac—PTGS2—Etoposide—peripheral nervous system neoplasm	0.0562	0.115	CbGbCtD
Sulindac—CYP1A2—Alitretinoin—peripheral nervous system neoplasm	0.0542	0.111	CbGbCtD
Sulindac—PTGS1—Etoposide—peripheral nervous system neoplasm	0.0475	0.097	CbGbCtD
Sulindac—CYP1A2—Dacarbazine—peripheral nervous system neoplasm	0.0433	0.0885	CbGbCtD
Sulindac—AKR1B1—sciatic nerve—peripheral nervous system neoplasm	0.0217	0.529	CbGeAlD
Sulindac—CYP1A2—Etoposide—peripheral nervous system neoplasm	0.0212	0.0433	CbGbCtD
Sulindac—AKR1B1—trigeminal ganglion—peripheral nervous system neoplasm	0.00315	0.0766	CbGeAlD
Sulindac—AKR1B1—parotid gland—peripheral nervous system neoplasm	0.00297	0.0723	CbGeAlD
Sulindac—PTGDR2—cerebellum—peripheral nervous system neoplasm	0.00259	0.0629	CbGeAlD
Sulindac—MAPK3—trigeminal ganglion—peripheral nervous system neoplasm	0.00228	0.0556	CbGeAlD
Sulindac—MAPK3—parotid gland—peripheral nervous system neoplasm	0.00216	0.0524	CbGeAlD
Sulindac—AKR1B1—cerebellum—peripheral nervous system neoplasm	0.00138	0.0334	CbGeAlD
Sulindac—PTGS1—ganglion—peripheral nervous system neoplasm	0.00126	0.0307	CbGeAlD
Sulindac—PPARD—cerebellum—peripheral nervous system neoplasm	0.00108	0.0263	CbGeAlD
Sulindac—MAPK3—cerebellum—peripheral nervous system neoplasm	0.000997	0.0242	CbGeAlD
Sulindac—CYP1A1—parotid gland—peripheral nervous system neoplasm	0.000667	0.0162	CbGeAlD
Sulindac—PTGS2—trigeminal ganglion—peripheral nervous system neoplasm	0.000594	0.0144	CbGeAlD
Sulindac—PTGS2—cerebellum—peripheral nervous system neoplasm	0.000259	0.0063	CbGeAlD
Sulindac—Tachycardia—Cisplatin—peripheral nervous system neoplasm	0.000219	0.000792	CcSEcCtD
Sulindac—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000219	0.000791	CcSEcCtD
Sulindac—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000219	0.000791	CcSEcCtD
Sulindac—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000219	0.000791	CcSEcCtD
Sulindac—Convulsion—Etoposide—peripheral nervous system neoplasm	0.000219	0.000789	CcSEcCtD
Sulindac—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000218	0.000788	CcSEcCtD
Sulindac—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000218	0.000787	CcSEcCtD
Sulindac—Headache—Tretinoin—peripheral nervous system neoplasm	0.000218	0.000787	CcSEcCtD
Sulindac—Hypertension—Etoposide—peripheral nervous system neoplasm	0.000218	0.000786	CcSEcCtD
Sulindac—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	0.000217	0.000784	CcSEcCtD
Sulindac—Constipation—Vincristine—peripheral nervous system neoplasm	0.000217	0.000784	CcSEcCtD
Sulindac—Gastrointestinal haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.000217	0.000784	CcSEcCtD
Sulindac—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.000217	0.000784	CcSEcCtD
Sulindac—Rash—Melphalan—peripheral nervous system neoplasm	0.000217	0.000782	CcSEcCtD
Sulindac—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000216	0.000781	CcSEcCtD
Sulindac—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.000216	0.000778	CcSEcCtD
Sulindac—Chest pain—Etoposide—peripheral nervous system neoplasm	0.000215	0.000775	CcSEcCtD
Sulindac—Anorexia—Cisplatin—peripheral nervous system neoplasm	0.000214	0.000773	CcSEcCtD
Sulindac—Discomfort—Etoposide—peripheral nervous system neoplasm	0.000212	0.000766	CcSEcCtD
Sulindac—Toxic epidermal necrolysis—Epirubicin—peripheral nervous system neoplasm	0.000211	0.000763	CcSEcCtD
Sulindac—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.00021	0.000758	CcSEcCtD
Sulindac—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.00021	0.000756	CcSEcCtD
Sulindac—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.000209	0.000756	CcSEcCtD
Sulindac—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000208	0.000752	CcSEcCtD
Sulindac—Nausea—Topotecan—peripheral nervous system neoplasm	0.000208	0.000752	CcSEcCtD
Sulindac—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000208	0.00075	CcSEcCtD
Sulindac—Gastritis—Epirubicin—peripheral nervous system neoplasm	0.000208	0.00075	CcSEcCtD
Sulindac—Muscular weakness—Epirubicin—peripheral nervous system neoplasm	0.000207	0.000747	CcSEcCtD
Sulindac—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000207	0.000746	CcSEcCtD
Sulindac—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000207	0.000746	CcSEcCtD
Sulindac—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.000206	0.000743	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000205	0.000739	CcSEcCtD
Sulindac—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000204	0.000737	CcSEcCtD
Sulindac—Nausea—Melphalan—peripheral nervous system neoplasm	0.000204	0.000736	CcSEcCtD
Sulindac—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.000202	0.000728	CcSEcCtD
Sulindac—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000202	0.000727	CcSEcCtD
Sulindac—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.000201	0.000725	CcSEcCtD
Sulindac—Eosinophilia—Epirubicin—peripheral nervous system neoplasm	0.000201	0.000725	CcSEcCtD
Sulindac—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000201	0.000725	CcSEcCtD
Sulindac—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.0002	0.000723	CcSEcCtD
Sulindac—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000199	0.000718	CcSEcCtD
Sulindac—Pancreatitis—Epirubicin—peripheral nervous system neoplasm	0.000199	0.000718	CcSEcCtD
Sulindac—Anorexia—Etoposide—peripheral nervous system neoplasm	0.000196	0.000708	CcSEcCtD
Sulindac—Toxic epidermal necrolysis—Doxorubicin—peripheral nervous system neoplasm	0.000196	0.000706	CcSEcCtD
Sulindac—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000195	0.000705	CcSEcCtD
Sulindac—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000195	0.000702	CcSEcCtD
Sulindac—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000194	0.000701	CcSEcCtD
Sulindac—Pancytopenia—Epirubicin—peripheral nervous system neoplasm	0.000193	0.000696	CcSEcCtD
Sulindac—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000192	0.000694	CcSEcCtD
Sulindac—Gastritis—Doxorubicin—peripheral nervous system neoplasm	0.000192	0.000694	CcSEcCtD
Sulindac—Muscular weakness—Doxorubicin—peripheral nervous system neoplasm	0.000192	0.000692	CcSEcCtD
Sulindac—Neutropenia—Epirubicin—peripheral nervous system neoplasm	0.00019	0.000685	CcSEcCtD
Sulindac—Dysuria—Epirubicin—peripheral nervous system neoplasm	0.00019	0.000685	CcSEcCtD
Sulindac—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000189	0.000683	CcSEcCtD
Sulindac—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000187	0.000676	CcSEcCtD
Sulindac—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000187	0.000673	CcSEcCtD
Sulindac—Eosinophilia—Doxorubicin—peripheral nervous system neoplasm	0.000186	0.000671	CcSEcCtD
Sulindac—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	0.000185	0.000669	CcSEcCtD
Sulindac—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000185	0.000668	CcSEcCtD
Sulindac—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000185	0.000667	CcSEcCtD
Sulindac—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	0.000184	0.000664	CcSEcCtD
Sulindac—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000184	0.000662	CcSEcCtD
Sulindac—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.000183	0.000661	CcSEcCtD
Sulindac—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000183	0.000661	CcSEcCtD
Sulindac—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000182	0.000658	CcSEcCtD
Sulindac—Pneumonia—Epirubicin—peripheral nervous system neoplasm	0.000182	0.000657	CcSEcCtD
Sulindac—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000181	0.000653	CcSEcCtD
Sulindac—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.00018	0.000651	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	0.000179	0.000647	CcSEcCtD
Sulindac—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000179	0.000647	CcSEcCtD
Sulindac—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000179	0.000646	CcSEcCtD
Sulindac—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000178	0.000644	CcSEcCtD
Sulindac—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000178	0.000642	CcSEcCtD
Sulindac—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000178	0.000641	CcSEcCtD
Sulindac—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000177	0.000641	CcSEcCtD
Sulindac—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	0.000177	0.00064	CcSEcCtD
Sulindac—Jaundice—Epirubicin—peripheral nervous system neoplasm	0.000176	0.000637	CcSEcCtD
Sulindac—Stomatitis—Epirubicin—peripheral nervous system neoplasm	0.000176	0.000637	CcSEcCtD
Sulindac—Constipation—Etoposide—peripheral nervous system neoplasm	0.000176	0.000635	CcSEcCtD
Sulindac—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	0.000176	0.000635	CcSEcCtD
Sulindac—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	0.000176	0.000634	CcSEcCtD
Sulindac—Dysuria—Doxorubicin—peripheral nervous system neoplasm	0.000176	0.000634	CcSEcCtD
Sulindac—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000174	0.000629	CcSEcCtD
Sulindac—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000174	0.000628	CcSEcCtD
Sulindac—Sweating—Epirubicin—peripheral nervous system neoplasm	0.000173	0.000626	CcSEcCtD
Sulindac—Haematuria—Epirubicin—peripheral nervous system neoplasm	0.000172	0.000623	CcSEcCtD
Sulindac—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	0.000171	0.000619	CcSEcCtD
Sulindac—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.000171	0.000616	CcSEcCtD
Sulindac—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.00017	0.000612	CcSEcCtD
Sulindac—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.000169	0.000611	CcSEcCtD
Sulindac—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000169	0.00061	CcSEcCtD
Sulindac—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	0.000169	0.000609	CcSEcCtD
Sulindac—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	0.000168	0.000608	CcSEcCtD
Sulindac—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000168	0.000608	CcSEcCtD
Sulindac—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000168	0.000607	CcSEcCtD
Sulindac—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000168	0.000605	CcSEcCtD
Sulindac—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000166	0.0006	CcSEcCtD
Sulindac—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000166	0.0006	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	0.000166	0.000599	CcSEcCtD
Sulindac—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000166	0.000598	CcSEcCtD
Sulindac—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000165	0.000596	CcSEcCtD
Sulindac—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.000165	0.000594	CcSEcCtD
Sulindac—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000164	0.000592	CcSEcCtD
Sulindac—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000164	0.00059	CcSEcCtD
Sulindac—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	0.000163	0.000589	CcSEcCtD
Sulindac—Jaundice—Doxorubicin—peripheral nervous system neoplasm	0.000163	0.000589	CcSEcCtD
Sulindac—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000163	0.000587	CcSEcCtD
Sulindac—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	0.000163	0.000587	CcSEcCtD
Sulindac—Hepatitis—Epirubicin—peripheral nervous system neoplasm	0.000162	0.000586	CcSEcCtD
Sulindac—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000162	0.000583	CcSEcCtD
Sulindac—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000161	0.000582	CcSEcCtD
Sulindac—Sweating—Doxorubicin—peripheral nervous system neoplasm	0.00016	0.000579	CcSEcCtD
Sulindac—Rash—Vincristine—peripheral nervous system neoplasm	0.00016	0.000578	CcSEcCtD
Sulindac—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.00016	0.000578	CcSEcCtD
Sulindac—Haematuria—Doxorubicin—peripheral nervous system neoplasm	0.00016	0.000576	CcSEcCtD
Sulindac—Headache—Vincristine—peripheral nervous system neoplasm	0.000159	0.000575	CcSEcCtD
Sulindac—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.000158	0.00057	CcSEcCtD
Sulindac—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000157	0.000565	CcSEcCtD
Sulindac—Visual impairment—Epirubicin—peripheral nervous system neoplasm	0.000157	0.000565	CcSEcCtD
Sulindac—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	0.000156	0.000564	CcSEcCtD
Sulindac—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000154	0.000555	CcSEcCtD
Sulindac—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	0.000154	0.000554	CcSEcCtD
Sulindac—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000152	0.000547	CcSEcCtD
Sulindac—Tinnitus—Epirubicin—peripheral nervous system neoplasm	0.000151	0.000547	CcSEcCtD
Sulindac—Nausea—Vincristine—peripheral nervous system neoplasm	0.000151	0.000545	CcSEcCtD
Sulindac—Flushing—Epirubicin—peripheral nervous system neoplasm	0.000151	0.000544	CcSEcCtD
Sulindac—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	0.00015	0.000542	CcSEcCtD
Sulindac—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000148	0.000533	CcSEcCtD
Sulindac—Chills—Epirubicin—peripheral nervous system neoplasm	0.000146	0.000526	CcSEcCtD
Sulindac—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000146	0.000526	CcSEcCtD
Sulindac—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	0.000145	0.000524	CcSEcCtD
Sulindac—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	0.000145	0.000523	CcSEcCtD
Sulindac—Alopecia—Epirubicin—peripheral nervous system neoplasm	0.000144	0.000518	CcSEcCtD
Sulindac—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000143	0.000516	CcSEcCtD
Sulindac—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	0.000142	0.000513	CcSEcCtD
Sulindac—Rash—Cisplatin—peripheral nervous system neoplasm	0.000142	0.000511	CcSEcCtD
Sulindac—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000142	0.000511	CcSEcCtD
Sulindac—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000141	0.000508	CcSEcCtD
Sulindac—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	0.00014	0.000506	CcSEcCtD
Sulindac—Flushing—Doxorubicin—peripheral nervous system neoplasm	0.000139	0.000503	CcSEcCtD
Sulindac—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.000139	0.000503	CcSEcCtD
Sulindac—Tension—Epirubicin—peripheral nervous system neoplasm	0.000139	0.000501	CcSEcCtD
Sulindac—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	0.000138	0.0005	CcSEcCtD
Sulindac—Nervousness—Epirubicin—peripheral nervous system neoplasm	0.000137	0.000496	CcSEcCtD
Sulindac—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000136	0.000491	CcSEcCtD
Sulindac—Chills—Doxorubicin—peripheral nervous system neoplasm	0.000135	0.000487	CcSEcCtD
Sulindac—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	0.000134	0.000485	CcSEcCtD
Sulindac—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000133	0.000482	CcSEcCtD
Sulindac—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000133	0.000481	CcSEcCtD
Sulindac—Alopecia—Doxorubicin—peripheral nervous system neoplasm	0.000133	0.000479	CcSEcCtD
Sulindac—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	0.000131	0.000473	CcSEcCtD
Sulindac—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000131	0.000472	CcSEcCtD
Sulindac—Anaemia—Epirubicin—peripheral nervous system neoplasm	0.000131	0.000472	CcSEcCtD
Sulindac—Rash—Etoposide—peripheral nervous system neoplasm	0.00013	0.000468	CcSEcCtD
Sulindac—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.00013	0.000468	CcSEcCtD
Sulindac—Headache—Etoposide—peripheral nervous system neoplasm	0.000129	0.000465	CcSEcCtD
Sulindac—Flatulence—Doxorubicin—peripheral nervous system neoplasm	0.000129	0.000465	CcSEcCtD
Sulindac—Tension—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.000463	CcSEcCtD
Sulindac—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.000462	CcSEcCtD
Sulindac—Malaise—Epirubicin—peripheral nervous system neoplasm	0.000127	0.00046	CcSEcCtD
Sulindac—Nervousness—Doxorubicin—peripheral nervous system neoplasm	0.000127	0.000459	CcSEcCtD
Sulindac—Vertigo—Epirubicin—peripheral nervous system neoplasm	0.000127	0.000458	CcSEcCtD
Sulindac—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000127	0.000458	CcSEcCtD
Sulindac—Leukopenia—Epirubicin—peripheral nervous system neoplasm	0.000127	0.000457	CcSEcCtD
Sulindac—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000125	0.000451	CcSEcCtD
Sulindac—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000124	0.000449	CcSEcCtD
Sulindac—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.000123	0.000445	CcSEcCtD
Sulindac—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.000122	0.000442	CcSEcCtD
Sulindac—Nausea—Etoposide—peripheral nervous system neoplasm	0.000122	0.000441	CcSEcCtD
Sulindac—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000122	0.000441	CcSEcCtD
Sulindac—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	0.000121	0.000438	CcSEcCtD
Sulindac—Anaemia—Doxorubicin—peripheral nervous system neoplasm	0.000121	0.000436	CcSEcCtD
Sulindac—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.00012	0.000434	CcSEcCtD
Sulindac—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.00012	0.000434	CcSEcCtD
Sulindac—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.00012	0.000434	CcSEcCtD
Sulindac—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000119	0.000429	CcSEcCtD
Sulindac—Malaise—Doxorubicin—peripheral nervous system neoplasm	0.000118	0.000426	CcSEcCtD
Sulindac—Vertigo—Doxorubicin—peripheral nervous system neoplasm	0.000118	0.000424	CcSEcCtD
Sulindac—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.000117	0.000423	CcSEcCtD
Sulindac—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	0.000117	0.000423	CcSEcCtD
Sulindac—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.000116	0.000417	CcSEcCtD
Sulindac—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	0.000115	0.000416	CcSEcCtD
Sulindac—Oedema—Epirubicin—peripheral nervous system neoplasm	0.000115	0.000416	CcSEcCtD
Sulindac—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.000115	0.000415	CcSEcCtD
Sulindac—Shock—Epirubicin—peripheral nervous system neoplasm	0.000114	0.00041	CcSEcCtD
Sulindac—Convulsion—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.000409	CcSEcCtD
Sulindac—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	0.000113	0.000408	CcSEcCtD
Sulindac—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.000408	CcSEcCtD
Sulindac—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000113	0.000406	CcSEcCtD
Sulindac—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.000112	0.000403	CcSEcCtD
Sulindac—Chest pain—Doxorubicin—peripheral nervous system neoplasm	0.000111	0.000402	CcSEcCtD
Sulindac—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.000111	0.000402	CcSEcCtD
Sulindac—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.000111	0.000402	CcSEcCtD
Sulindac—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.00011	0.000397	CcSEcCtD
Sulindac—Anorexia—Epirubicin—peripheral nervous system neoplasm	0.00011	0.000397	CcSEcCtD
Sulindac—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.000108	0.000389	CcSEcCtD
Sulindac—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000385	CcSEcCtD
Sulindac—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000385	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000105	0.000379	CcSEcCtD
Sulindac—Shock—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000379	CcSEcCtD
Sulindac—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000377	CcSEcCtD
Sulindac—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000377	CcSEcCtD
Sulindac—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.000376	CcSEcCtD
Sulindac—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000374	CcSEcCtD
Sulindac—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000373	CcSEcCtD
Sulindac—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000103	0.000371	CcSEcCtD
Sulindac—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000103	0.00037	CcSEcCtD
Sulindac—Anorexia—Doxorubicin—peripheral nervous system neoplasm	0.000102	0.000367	CcSEcCtD
Sulindac—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000102	0.000367	CcSEcCtD
Sulindac—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.0001	0.000362	CcSEcCtD
Sulindac—Hypotension—Doxorubicin—peripheral nervous system neoplasm	9.98e-05	0.00036	CcSEcCtD
Sulindac—Fatigue—Epirubicin—peripheral nervous system neoplasm	9.95e-05	0.000359	CcSEcCtD
Sulindac—Constipation—Epirubicin—peripheral nervous system neoplasm	9.87e-05	0.000356	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	9.73e-05	0.000351	CcSEcCtD
Sulindac—Insomnia—Doxorubicin—peripheral nervous system neoplasm	9.66e-05	0.000349	CcSEcCtD
Sulindac—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	9.59e-05	0.000346	CcSEcCtD
Sulindac—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	9.52e-05	0.000344	CcSEcCtD
Sulindac—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	9.51e-05	0.000343	CcSEcCtD
Sulindac—Somnolence—Doxorubicin—peripheral nervous system neoplasm	9.49e-05	0.000343	CcSEcCtD
Sulindac—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	9.43e-05	0.000341	CcSEcCtD
Sulindac—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	9.4e-05	0.000339	CcSEcCtD
Sulindac—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	9.28e-05	0.000335	CcSEcCtD
Sulindac—Fatigue—Doxorubicin—peripheral nervous system neoplasm	9.2e-05	0.000332	CcSEcCtD
Sulindac—Urticaria—Epirubicin—peripheral nervous system neoplasm	9.17e-05	0.000331	CcSEcCtD
Sulindac—Constipation—Doxorubicin—peripheral nervous system neoplasm	9.13e-05	0.00033	CcSEcCtD
Sulindac—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	9.12e-05	0.000329	CcSEcCtD
Sulindac—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	8.8e-05	0.000318	CcSEcCtD
Sulindac—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	8.73e-05	0.000315	CcSEcCtD
Sulindac—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	8.5e-05	0.000307	CcSEcCtD
Sulindac—Urticaria—Doxorubicin—peripheral nervous system neoplasm	8.48e-05	0.000306	CcSEcCtD
Sulindac—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	8.44e-05	0.000305	CcSEcCtD
Sulindac—Asthenia—Epirubicin—peripheral nervous system neoplasm	8.28e-05	0.000299	CcSEcCtD
Sulindac—Pruritus—Epirubicin—peripheral nervous system neoplasm	8.16e-05	0.000295	CcSEcCtD
Sulindac—MAPK3—DAP12 interactions—NRAS—peripheral nervous system neoplasm	8.01e-05	0.000416	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR in disease—NRAS—peripheral nervous system neoplasm	8.01e-05	0.000416	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—CDKN2A—peripheral nervous system neoplasm	8e-05	0.000416	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR—NRAS—peripheral nervous system neoplasm	7.94e-05	0.000413	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	7.92e-05	0.000412	CbGpPWpGaD
Sulindac—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	7.89e-05	0.000285	CcSEcCtD
Sulindac—MAPK3—Hemostasis—HGF—peripheral nervous system neoplasm	7.88e-05	0.00041	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—NRAS—peripheral nervous system neoplasm	7.87e-05	0.000409	CbGpPWpGaD
Sulindac—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	7.87e-05	0.000284	CcSEcCtD
Sulindac—PTGS2—Spinal Cord Injury—CASP3—peripheral nervous system neoplasm	7.86e-05	0.000409	CbGpPWpGaD
Sulindac—MAPK3—ErbB1 downstream signaling—AKT1—peripheral nervous system neoplasm	7.86e-05	0.000409	CbGpPWpGaD
Sulindac—MAPK3—Signaling by PDGF—NRAS—peripheral nervous system neoplasm	7.83e-05	0.000407	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—MYC—peripheral nervous system neoplasm	7.78e-05	0.000404	CbGpPWpGaD
Sulindac—MAPK3—PDGFR-beta signaling pathway—HRAS—peripheral nervous system neoplasm	7.74e-05	0.000402	CbGpPWpGaD
Sulindac—MAPK3—VEGFA-VEGFR2 Pathway—AKT1—peripheral nervous system neoplasm	7.74e-05	0.000402	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PPP3R1—peripheral nervous system neoplasm	7.72e-05	0.000401	CbGpPWpGaD
Sulindac—Asthenia—Doxorubicin—peripheral nervous system neoplasm	7.66e-05	0.000276	CcSEcCtD
Sulindac—Dizziness—Epirubicin—peripheral nervous system neoplasm	7.63e-05	0.000275	CcSEcCtD
Sulindac—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—peripheral nervous system neoplasm	7.58e-05	0.000394	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—BIRC5—peripheral nervous system neoplasm	7.57e-05	0.000393	CbGpPWpGaD
Sulindac—Pruritus—Doxorubicin—peripheral nervous system neoplasm	7.55e-05	0.000273	CcSEcCtD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	7.38e-05	0.000384	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—HGF—peripheral nervous system neoplasm	7.36e-05	0.000382	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	7.35e-05	0.000382	CbGpPWpGaD
Sulindac—Vomiting—Epirubicin—peripheral nervous system neoplasm	7.34e-05	0.000265	CcSEcCtD
Sulindac—MAPK3—Signaling by VEGF—AKT1—peripheral nervous system neoplasm	7.31e-05	0.00038	CbGpPWpGaD
Sulindac—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	7.3e-05	0.000264	CcSEcCtD
Sulindac—Rash—Epirubicin—peripheral nervous system neoplasm	7.27e-05	0.000263	CcSEcCtD
Sulindac—Dermatitis—Epirubicin—peripheral nervous system neoplasm	7.27e-05	0.000262	CcSEcCtD
Sulindac—Headache—Epirubicin—peripheral nervous system neoplasm	7.23e-05	0.000261	CcSEcCtD
Sulindac—MAPK3—Signaling by NGF—ERBB2—peripheral nervous system neoplasm	7.17e-05	0.000373	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NTS—peripheral nervous system neoplasm	7.14e-05	0.000371	CbGpPWpGaD
Sulindac—MAPK3—Disease—PPP3R1—peripheral nervous system neoplasm	7.13e-05	0.000371	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—NRAS—peripheral nervous system neoplasm	7.09e-05	0.000369	CbGpPWpGaD
Sulindac—Dizziness—Doxorubicin—peripheral nervous system neoplasm	7.06e-05	0.000255	CcSEcCtD
Sulindac—MAPK3—Signaling by SCF-KIT—HRAS—peripheral nervous system neoplasm	7.03e-05	0.000365	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—HSD17B12—peripheral nervous system neoplasm	7.02e-05	0.000365	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	7.02e-05	0.000365	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.91e-05	0.000359	CbGpPWpGaD
Sulindac—MAPK3—BDNF signaling pathway—HRAS—peripheral nervous system neoplasm	6.91e-05	0.000359	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	6.86e-05	0.000356	CbGpPWpGaD
Sulindac—Nausea—Epirubicin—peripheral nervous system neoplasm	6.85e-05	0.000247	CcSEcCtD
Sulindac—MAPK3—Signaling Pathways—CD55—peripheral nervous system neoplasm	6.84e-05	0.000356	CbGpPWpGaD
Sulindac—PPARD—Generic Transcription Pathway—MYC—peripheral nervous system neoplasm	6.83e-05	0.000355	CbGpPWpGaD
Sulindac—MAPK3—Immune System—NCAM1—peripheral nervous system neoplasm	6.82e-05	0.000355	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.79e-05	0.000353	CbGpPWpGaD
Sulindac—Vomiting—Doxorubicin—peripheral nervous system neoplasm	6.79e-05	0.000245	CcSEcCtD
Sulindac—MAPK3—Cell Cycle—BIRC5—peripheral nervous system neoplasm	6.77e-05	0.000352	CbGpPWpGaD
Sulindac—Rash—Doxorubicin—peripheral nervous system neoplasm	6.73e-05	0.000243	CcSEcCtD
Sulindac—MAPK3—Downstream signaling of activated FGFR—HRAS—peripheral nervous system neoplasm	6.73e-05	0.00035	CbGpPWpGaD
Sulindac—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	6.73e-05	0.000243	CcSEcCtD
Sulindac—Headache—Doxorubicin—peripheral nervous system neoplasm	6.69e-05	0.000241	CcSEcCtD
Sulindac—SLC22A6—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	6.63e-05	0.000345	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB4—HRAS—peripheral nervous system neoplasm	6.62e-05	0.000344	CbGpPWpGaD
Sulindac—PPARD—Metabolism—GNAS—peripheral nervous system neoplasm	6.57e-05	0.000342	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—CASP3—peripheral nervous system neoplasm	6.51e-05	0.000338	CbGpPWpGaD
Sulindac—SLC22A6—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	6.5e-05	0.000338	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—ERBB2—peripheral nervous system neoplasm	6.49e-05	0.000337	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—TP53—peripheral nervous system neoplasm	6.49e-05	0.000337	CbGpPWpGaD
Sulindac—PPARD—Metabolism—ABCB1—peripheral nervous system neoplasm	6.45e-05	0.000335	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—GNS—peripheral nervous system neoplasm	6.4e-05	0.000333	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—TP53—peripheral nervous system neoplasm	6.39e-05	0.000332	CbGpPWpGaD
Sulindac—MAPK3—Insulin Signaling—HRAS—peripheral nervous system neoplasm	6.35e-05	0.00033	CbGpPWpGaD
Sulindac—Nausea—Doxorubicin—peripheral nervous system neoplasm	6.34e-05	0.000229	CcSEcCtD
Sulindac—MAPK3—Developmental Biology—MET—peripheral nervous system neoplasm	6.34e-05	0.00033	CbGpPWpGaD
Sulindac—PTGS2—C-MYB transcription factor network—HRAS—peripheral nervous system neoplasm	6.33e-05	0.000329	CbGpPWpGaD
Sulindac—MAPK3—Downstream signal transduction—HRAS—peripheral nervous system neoplasm	6.32e-05	0.000329	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR—HRAS—peripheral nervous system neoplasm	6.29e-05	0.000327	CbGpPWpGaD
Sulindac—MAPK3—Regulation of toll-like receptor signaling pathway—AKT1—peripheral nervous system neoplasm	6.28e-05	0.000326	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB2—HRAS—peripheral nervous system neoplasm	6.26e-05	0.000325	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—HSD17B12—peripheral nervous system neoplasm	6.23e-05	0.000324	CbGpPWpGaD
Sulindac—MAPK3—DAP12 signaling—HRAS—peripheral nervous system neoplasm	6.23e-05	0.000324	CbGpPWpGaD
Sulindac—MAPK3—Signaling by SCF-KIT—AKT1—peripheral nervous system neoplasm	6.21e-05	0.000323	CbGpPWpGaD
Sulindac—MAPK3—Disease—ENO2—peripheral nervous system neoplasm	6.18e-05	0.000321	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—MYC—peripheral nervous system neoplasm	6.14e-05	0.000319	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—NME1—peripheral nervous system neoplasm	6.13e-05	0.000319	CbGpPWpGaD
Sulindac—MAPK3—BDNF signaling pathway—AKT1—peripheral nervous system neoplasm	6.1e-05	0.000317	CbGpPWpGaD
Sulindac—PTGS2—Disease—GNS—peripheral nervous system neoplasm	6.06e-05	0.000315	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling of activated FGFR—AKT1—peripheral nervous system neoplasm	5.94e-05	0.000309	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—COX2—peripheral nervous system neoplasm	5.9e-05	0.000307	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	5.89e-05	0.000306	CbGpPWpGaD
Sulindac—MAPK3—Cellular Senescence—TP53—peripheral nervous system neoplasm	5.89e-05	0.000306	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	5.88e-05	0.000306	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—PTPN11—peripheral nervous system neoplasm	5.86e-05	0.000305	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR in disease—HRAS—peripheral nervous system neoplasm	5.86e-05	0.000305	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—HRAS—peripheral nervous system neoplasm	5.86e-05	0.000305	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—HRAS—peripheral nervous system neoplasm	5.86e-05	0.000305	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB4—AKT1—peripheral nervous system neoplasm	5.84e-05	0.000304	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	5.84e-05	0.000303	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR—HRAS—peripheral nervous system neoplasm	5.81e-05	0.000302	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	5.8e-05	0.000301	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	5.77e-05	0.0003	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—HRAS—peripheral nervous system neoplasm	5.76e-05	0.000299	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—PTPN11—peripheral nervous system neoplasm	5.75e-05	0.000299	CbGpPWpGaD
Sulindac—MAPK3—Signaling by PDGF—HRAS—peripheral nervous system neoplasm	5.73e-05	0.000298	CbGpPWpGaD
Sulindac—ALB—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.68e-05	0.000295	CbGpPWpGaD
Sulindac—MAPK3—Insulin Signaling—AKT1—peripheral nervous system neoplasm	5.61e-05	0.000292	CbGpPWpGaD
Sulindac—MAPK3—Downstream signal transduction—AKT1—peripheral nervous system neoplasm	5.58e-05	0.00029	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR—AKT1—peripheral nervous system neoplasm	5.55e-05	0.000289	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—NRAS—peripheral nervous system neoplasm	5.55e-05	0.000289	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB2—AKT1—peripheral nervous system neoplasm	5.53e-05	0.000287	CbGpPWpGaD
Sulindac—MAPK3—DAP12 signaling—AKT1—peripheral nervous system neoplasm	5.5e-05	0.000286	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—NRAS—peripheral nervous system neoplasm	5.46e-05	0.000284	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	5.43e-05	0.000282	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—VIP—peripheral nervous system neoplasm	5.41e-05	0.000281	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—AKT1—peripheral nervous system neoplasm	5.39e-05	0.000281	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.37e-05	0.000279	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IFNB1—peripheral nervous system neoplasm	5.35e-05	0.000278	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	5.35e-05	0.000278	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—HRAS—peripheral nervous system neoplasm	5.19e-05	0.00027	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	5.18e-05	0.000269	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—PTPN11—peripheral nervous system neoplasm	5.18e-05	0.000269	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—AKT1—peripheral nervous system neoplasm	5.17e-05	0.000269	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR in disease—AKT1—peripheral nervous system neoplasm	5.17e-05	0.000269	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—AKT1—peripheral nervous system neoplasm	5.17e-05	0.000269	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR—AKT1—peripheral nervous system neoplasm	5.13e-05	0.000267	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—AKT1—peripheral nervous system neoplasm	5.08e-05	0.000264	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GNS—peripheral nervous system neoplasm	5.08e-05	0.000264	CbGpPWpGaD
Sulindac—MAPK3—Signaling by PDGF—AKT1—peripheral nervous system neoplasm	5.06e-05	0.000263	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	5.06e-05	0.000263	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—TP53—peripheral nervous system neoplasm	5.04e-05	0.000262	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	5.02e-05	0.000261	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—CDKN2A—peripheral nervous system neoplasm	5.01e-05	0.000261	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	4.99e-05	0.00026	CbGpPWpGaD
Sulindac—MAPK3—Disease—SLC2A1—peripheral nervous system neoplasm	4.98e-05	0.000259	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—NRAS—peripheral nervous system neoplasm	4.94e-05	0.000257	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.92e-05	0.000256	CbGpPWpGaD
Sulindac—ALB—Hemostasis—IFNB1—peripheral nervous system neoplasm	4.91e-05	0.000255	CbGpPWpGaD
Sulindac—AKR1B1—Metabolism—AKT1—peripheral nervous system neoplasm	4.9e-05	0.000255	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.87e-05	0.000253	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	4.87e-05	0.000253	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—NME1—peripheral nervous system neoplasm	4.87e-05	0.000253	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	4.75e-05	0.000247	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	4.72e-05	0.000245	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—COX2—peripheral nervous system neoplasm	4.69e-05	0.000244	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—ERBB2—peripheral nervous system neoplasm	4.63e-05	0.000241	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	4.58e-05	0.000238	CbGpPWpGaD
Sulindac—ALB—Hemostasis—KNG1—peripheral nervous system neoplasm	4.55e-05	0.000237	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GNS—peripheral nervous system neoplasm	4.51e-05	0.000234	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—CDKN2A—peripheral nervous system neoplasm	4.48e-05	0.000233	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.47e-05	0.000232	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—TP53—peripheral nervous system neoplasm	4.45e-05	0.000231	CbGpPWpGaD
Sulindac—MAPK3—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	4.33e-05	0.000225	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—NME1—peripheral nervous system neoplasm	4.32e-05	0.000225	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	4.28e-05	0.000223	CbGpPWpGaD
Sulindac—PTGS2—Disease—PPP3R1—peripheral nervous system neoplasm	4.24e-05	0.00022	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	4.17e-05	0.000217	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—COX2—peripheral nervous system neoplasm	4.16e-05	0.000216	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HGF—peripheral nervous system neoplasm	4.13e-05	0.000215	CbGpPWpGaD
Sulindac—ALB—Metabolism—GNS—peripheral nervous system neoplasm	4.11e-05	0.000214	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—ERBB2—peripheral nervous system neoplasm	4.09e-05	0.000213	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.08e-05	0.000212	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—HRAS—peripheral nervous system neoplasm	4.06e-05	0.000211	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—HRAS—peripheral nervous system neoplasm	3.99e-05	0.000208	CbGpPWpGaD
Sulindac—ALB—Hemostasis—GNAS—peripheral nervous system neoplasm	3.98e-05	0.000207	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—HSD17B12—peripheral nervous system neoplasm	3.97e-05	0.000207	CbGpPWpGaD
Sulindac—ALB—Metabolism—NME1—peripheral nervous system neoplasm	3.94e-05	0.000205	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—ENO2—peripheral nervous system neoplasm	3.87e-05	0.000201	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.8e-05	0.000198	CbGpPWpGaD
Sulindac—ALB—Hemostasis—HGF—peripheral nervous system neoplasm	3.79e-05	0.000197	CbGpPWpGaD
Sulindac—ALB—Metabolism—COX2—peripheral nervous system neoplasm	3.79e-05	0.000197	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	3.75e-05	0.000195	CbGpPWpGaD
Sulindac—PTGS2—Disease—ENO2—peripheral nervous system neoplasm	3.67e-05	0.000191	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—HRAS—peripheral nervous system neoplasm	3.61e-05	0.000188	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—AKT1—peripheral nervous system neoplasm	3.52e-05	0.000183	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—NRAS—peripheral nervous system neoplasm	3.52e-05	0.000183	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—NRAS—peripheral nervous system neoplasm	3.46e-05	0.00018	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	3.45e-05	0.000179	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	3.43e-05	0.000178	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—MYC—peripheral nervous system neoplasm	3.4e-05	0.000177	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	3.38e-05	0.000176	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	3.3e-05	0.000172	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	3.3e-05	0.000172	CbGpPWpGaD
Sulindac—PPARD—Gene Expression—MYC—peripheral nervous system neoplasm	3.29e-05	0.000171	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—BCHE—peripheral nervous system neoplasm	3.27e-05	0.00017	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—KNG1—peripheral nervous system neoplasm	3.21e-05	0.000167	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.12e-05	0.000162	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.12e-05	0.000162	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—NRAS—peripheral nervous system neoplasm	3.11e-05	0.000162	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—TH—peripheral nervous system neoplasm	3.08e-05	0.00016	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ENO2—peripheral nervous system neoplasm	3.08e-05	0.00016	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.06e-05	0.000159	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—MYC—peripheral nervous system neoplasm	3.04e-05	0.000158	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PTPN11—peripheral nervous system neoplasm	3.01e-05	0.000157	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.99e-05	0.000155	CbGpPWpGaD
Sulindac—PTGS2—Disease—SLC2A1—peripheral nervous system neoplasm	2.96e-05	0.000154	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	2.9e-05	0.000151	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GNS—peripheral nervous system neoplasm	2.87e-05	0.000149	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.8e-05	0.000146	CbGpPWpGaD
Sulindac—MAPK3—Disease—PTPN11—peripheral nervous system neoplasm	2.78e-05	0.000145	CbGpPWpGaD
Sulindac—ALB—Hemostasis—PTPN11—peripheral nervous system neoplasm	2.77e-05	0.000144	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NME1—peripheral nervous system neoplasm	2.75e-05	0.000143	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ENO2—peripheral nervous system neoplasm	2.73e-05	0.000142	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—COX2—peripheral nervous system neoplasm	2.65e-05	0.000138	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—TP53—peripheral nervous system neoplasm	2.64e-05	0.000137	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.64e-05	0.000137	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—BCHE—peripheral nervous system neoplasm	2.6e-05	0.000135	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—HRAS—peripheral nervous system neoplasm	2.58e-05	0.000134	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—HRAS—peripheral nervous system neoplasm	2.53e-05	0.000131	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—GNAS—peripheral nervous system neoplasm	2.51e-05	0.000131	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—TP53—peripheral nervous system neoplasm	2.5e-05	0.00013	CbGpPWpGaD
Sulindac—ALB—Metabolism—ENO2—peripheral nervous system neoplasm	2.49e-05	0.000129	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.48e-05	0.000129	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—ABCB1—peripheral nervous system neoplasm	2.47e-05	0.000128	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—TH—peripheral nervous system neoplasm	2.44e-05	0.000127	CbGpPWpGaD
Sulindac—MAPK3—Immune System—ERBB2—peripheral nervous system neoplasm	2.38e-05	0.000124	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—BCHE—peripheral nervous system neoplasm	2.31e-05	0.00012	CbGpPWpGaD
Sulindac—PPARD—Gene Expression—AKT1—peripheral nervous system neoplasm	2.28e-05	0.000119	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—HRAS—peripheral nervous system neoplasm	2.28e-05	0.000118	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—AKT1—peripheral nervous system neoplasm	2.28e-05	0.000118	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—AKT1—peripheral nervous system neoplasm	2.23e-05	0.000116	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.2e-05	0.000114	CbGpPWpGaD
Sulindac—MAPK3—Disease—ERBB2—peripheral nervous system neoplasm	2.2e-05	0.000114	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—TH—peripheral nervous system neoplasm	2.17e-05	0.000113	CbGpPWpGaD
Sulindac—ALB—Metabolism—BCHE—peripheral nervous system neoplasm	2.1e-05	0.000109	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	2.08e-05	0.000108	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—AKT1—peripheral nervous system neoplasm	2.01e-05	0.000105	CbGpPWpGaD
Sulindac—ALB—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.01e-05	0.000104	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GNAS—peripheral nervous system neoplasm	1.99e-05	0.000104	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.98e-05	0.000103	CbGpPWpGaD
Sulindac—ALB—Metabolism—TH—peripheral nervous system neoplasm	1.98e-05	0.000103	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ABCB1—peripheral nervous system neoplasm	1.96e-05	0.000102	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.95e-05	0.000101	CbGpPWpGaD
Sulindac—MAPK3—Immune System—NRAS—peripheral nervous system neoplasm	1.81e-05	9.43e-05	CbGpPWpGaD
Sulindac—PPARD—Metabolism—AKT1—peripheral nervous system neoplasm	1.77e-05	9.22e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GNAS—peripheral nervous system neoplasm	1.77e-05	9.21e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ENO2—peripheral nervous system neoplasm	1.74e-05	9.05e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ABCB1—peripheral nervous system neoplasm	1.74e-05	9.03e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—MYC—peripheral nervous system neoplasm	1.68e-05	8.73e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—NRAS—peripheral nervous system neoplasm	1.67e-05	8.7e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—NRAS—peripheral nervous system neoplasm	1.66e-05	8.65e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PTPN11—peripheral nervous system neoplasm	1.66e-05	8.61e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—GNAS—peripheral nervous system neoplasm	1.61e-05	8.39e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—ABCB1—peripheral nervous system neoplasm	1.58e-05	8.23e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—MYC—peripheral nervous system neoplasm	1.56e-05	8.11e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.54e-05	8.01e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—BCHE—peripheral nervous system neoplasm	1.47e-05	7.65e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.45e-05	7.55e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.4e-05	7.29e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.4e-05	7.27e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—TH—peripheral nervous system neoplasm	1.38e-05	7.19e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HRAS—peripheral nervous system neoplasm	1.33e-05	6.9e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—ERBB2—peripheral nervous system neoplasm	1.31e-05	6.8e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.28e-05	6.66e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TP53—peripheral nervous system neoplasm	1.27e-05	6.62e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—HRAS—peripheral nervous system neoplasm	1.22e-05	6.37e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—HRAS—peripheral nervous system neoplasm	1.22e-05	6.33e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.17e-05	6.09e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—AKT1—peripheral nervous system neoplasm	1.17e-05	6.09e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—AKT1—peripheral nervous system neoplasm	1.16e-05	6.05e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GNAS—peripheral nervous system neoplasm	1.13e-05	5.87e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ABCB1—peripheral nervous system neoplasm	1.11e-05	5.76e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.09e-05	5.68e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—AKT1—peripheral nervous system neoplasm	1.08e-05	5.62e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—AKT1—peripheral nervous system neoplasm	1.07e-05	5.59e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—NRAS—peripheral nervous system neoplasm	9.95e-06	5.17e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MYC—peripheral nervous system neoplasm	9.27e-06	4.82e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TP53—peripheral nervous system neoplasm	8.97e-06	4.66e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.57e-06	4.46e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.57e-06	3.94e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—HRAS—peripheral nervous system neoplasm	7.28e-06	3.79e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—AKT1—peripheral nervous system neoplasm	6.78e-06	3.53e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—AKT1—peripheral nervous system neoplasm	6.43e-06	3.34e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—AKT1—peripheral nervous system neoplasm	5.38e-06	2.8e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—AKT1—peripheral nervous system neoplasm	4.78e-06	2.48e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—AKT1—peripheral nervous system neoplasm	4.36e-06	2.26e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—AKT1—peripheral nervous system neoplasm	3.05e-06	1.58e-05	CbGpPWpGaD
